On October 14, 2026, the Food and Drug Administration (FDA) announced the launch of a Rare Disease Framework Initiative to advance a regulatory framework “purpose-built” for the development and review of rare disease therapies. Developing therapies for very small patient populations can present challenges in drug development and the vast majority of rare diseases have no FDA-approved treatments. This initiative is intended to help respond to these challenges.